Research at Artica Therapeutics BV has led to the development of C-C chemokine receptor type 2 (CCR2B) antagonists reported to be useful for the treatment of cancer.
Breast cancer (BC) is a prevalent form of cancer among women globally. Recent studies suggest that circular RNA (circRNA) plays a significant role in BC progression, but the biological functions and underlying mechanisms remain unexplored. According to a recent study published in the Journal of Translational Medicine, the interaction between circDNAJC11 and TATA-box-binding protein-associated factor 15 (TAF15) promotes BC progression through the upregulation of MAPK6 expression and activation of the MAPK signaling pathway.
Phase II data that rolled out from Merck KGaA with its Bruton's tyrosine kinase (BTK) inhibitor evobrutinib in relapsed multiple sclerosis (MS) put more eyeballs on the mechanism. It’s already well validated in oncology, but resistance has arisen there, and at least two firms – Beigene Ltd. and Nurix Therapeutics Inc. – are striving for solutions with degrader candidates.
Northwest Agriculture & Forestry University has described thiazolecarboxamidine compounds acting as NADH-ubiquinone oxidoreductase (complex I) inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12C) mutant inhibitors reported to be useful for the treatment of cancer.
RSS
